CoreAge Rx vs the Other Flat-Price GLP-1 Programs: Who Really Locks Your Rate?

The word “flat” is doing a lot of work on GLP-1 landing pages this year. CoreAge Rx puts it right at the top — $99 compounded semaglutide, $149 compounded tirzepatide, same price at every dose — and so do at least four other programs I lined up against it. This CoreAge Rx vs flat-price GLP-1 comparison exists because “flat” turns out to mean something a little different on each of those sites, and the gap between them is where your month-eight budget actually lives.

Here’s the thing most shoppers miss. The scary number in a GLP-1 plan isn’t the sticker on day one. It’s what happens when your prescriber moves you from a 2.5 mg starter dose up toward a maintenance dose, because on a lot of platforms that titration quietly drags the monthly bill up $100 or more. A genuine flat-price pledge freezes that. A fake one just freezes the intro rate for a while.

What CoreAge Rx Actually Locks

CoreAge Rx lists compounded semaglutide starting at $99 a month and compounded tirzepatide starting at $149 a month, with the line “same price at every dose” attached to both, plus free shipping and no separate membership fee. When the company announced the flat-rate structure in January 2026, the fine print showed the catch: those headline numbers are the annual-prepay rate. Pay month to month and you’ll pay more. Pay for the year and the dose-escalation freeze is real — the same $149 whether you’re on a 5 mg or a 12.5 mg tirzepatide dose.

That dose clause is the part worth caring about. Brand Mounjaro and Zepbound run past $1,000 a month at retail, so a compounded program holding $149 across a full year of titration is a real difference, not a rounding error. My one gripe: the “starting at” wording. Starting at $99 is not the same promise as “$99, forever, no matter what,” and the two get blurred on the page. Screenshot the checkout terms before you enter a card. If the number that renews matches the number you were quoted, good. If it doesn’t, you found the trapdoor early.

How the Flat-Price Field Stacks Up

I put CoreAge Rx next to three other programs that lean on flat or fixed pricing in their marketing. The numbers move around with promotions, so treat these as the rates I saw, not carved stone.

Program	Semaglutide (mo)	Tirzepatide (mo)	What “flat” means here
CoreAge Rx	From $99	From $149	Same price at every dose, annual prepay for the headline rate
Trimi	$99	$125	Flat at every dose, all-inclusive, annual billing
TrimRx	From $174	$349 flat	Tirzepatide holds at every dose; semaglutide tiered by plan length
BreezeMeds	Varies	Varies	Promo-driven; dose freeze not clearly stated

Two things jump out. Trimi undercuts CoreAge on tirzepatide by about $24 a month, which adds up to nearly $300 over a year. But CoreAge’s semaglutide entry point matches Trimi’s $99 exactly. So the “who’s cheapest” answer flips depending on which molecule your prescriber puts you on. That’s the whole reason a face-off beats a single review — the winner isn’t fixed.

The CoreAge Rx vs Everyone Verdict on “Forever”

None of these companies can promise a price literally forever, and here’s the uncomfortable reason. Compounded semaglutide and tirzepatide aren’t FDA-approved products. They’re made by compounding pharmacies, they require a prescription, and whether you get one is a decision your prescriber makes, not a box you check. That whole category also sits under a moving regulatory cloud: the FDA declared the tirzepatide shortage resolved in 2024 and semaglutide in 2025, and in April 2026 it proposed removing both from the 503B bulk-compounding list entirely. A pricing pledge from any of these brands is only as durable as their access to the ingredient.

So “who really locks your rate” has a two-part answer. On paper, CoreAge Rx and Trimi lock it hardest, because both freeze the dose-escalation jump that quietly wrecks most other budgets. In reality, no compounded program can outrun a rule change in Washington. Read the pledge, screenshot it, and don’t prepay a full year with a company you can’t reach by phone.

Who CoreAge Rx Fits

If you already know you want tirzepatide and you’re comparing on nothing but price, Trimi’s $125 edges it. If you’re leaning toward semaglutide, or you want the dose freeze plus free shipping bundled without hunting for coupon codes, CoreAge Rx is a clean, honest pick at $99. The people who should slow down are anyone expecting hand-holding. This is a lean, price-first program — a quick intake, a prescriber review, and your medication. Around 42% of US adults meet the clinical definition of obesity, per NIH figures, and a big share of them are shopping exactly this way: on price, dose by dose.

Is CoreAge Rx’s flat price really the same at every dose?

That’s the claim, and it’s the strongest part of the offer — the same monthly rate whether you’re on a starter or a maintenance dose, provided you’re on the annual-prepay plan. Month-to-month pricing is higher. Confirm the renewing amount at checkout in writing before you commit.

Is CoreAge Rx cheaper than Trimi or TrimRx?

It depends on the molecule. CoreAge and Trimi tie on semaglutide at $99. Trimi’s tirzepatide ($125) beats CoreAge’s ($149). Both undercut TrimRx, whose tirzepatide runs $349 a month. If tirzepatide is your target, price out all three before signing.

Is compounded tirzepatide from CoreAge Rx FDA-approved?

No. Compounded tirzepatide is not an FDA-approved product. It’s prepared by a compounding pharmacy, requires a valid prescription, and a licensed prescriber decides whether it’s appropriate for you. That’s true of every compounded GLP-1, not just CoreAge Rx.

What happens to the price if I switch from semaglutide to tirzepatide?

You move from the $99 tier to the $149 tier — the dose freeze applies within a medication, not across a switch. Any change in molecule is a new prescribing decision, so talk to the provider before assuming the flat rate carries over.